The t:slim X2 Insulin Pump from Tandem Diabetes Care with Abbott’s Freestyle Libre 2 Plus sensor integration is now available in the US. Credit: Abbott/Business Wire.

Abbott has announced that Tandem Diabetes Care’s t:slim X2 insulin pump has become the first automated insulin delivery (AID) system to integrate with its newly available FreeStyle Libre 2 Plus sensor.  

This advancement allows users of the FreeStyle Libre technology in the US to benefit from a hybrid closed-loop system that helps predict and prevent high and low blood sugar levels. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Featuring Control-IQ technology, the t:slim X2 insulin pump now wirelessly connects to the FreeStyle Libre 2 Plus sensor.  

This sensor provides glucose readings every minute, which are displayed on the pump and the t:connect mobile app.  

Furthermore, the glucose levels are anticipated by the Control-IQ technology about 30 minutes ahead, adjusting insulin delivery accordingly to prevent hyperglycemia. 

Tandem Diabetes Care president and CEO John Sheridan said: “Tandem’s leadership in AID innovation is underscored with this milestone of launching the first insulin pump to be compatible with Abbott’s CGM technology in the US.  

“This represents another step forward in our commitment to provide customisable solutions to help reduce burden and create new possibilities for people living with diabetes.” 

Abbott’s FreeStyle Libre 2 Plus sensor, cleared by the US Food and Drug Administration (FDA), is said to be the only continuous glucose monitoring sensor in the country that offers a 15-day wear time for both adults and children.  

Tandem is providing in-warranty t:slim X2 users in the US with instructions to integrate the new FreeStyle Libre 2 Plus sensor through a remote software update, at no additional cost.  

New customers will receive pumps pre-loaded with the updated software.  

Abbott diabetes care business executive vice-president Jared Watkin said: “Through the integration of Tandem’s t:slim X2 insulin pump with our FreeStyle Libre 2 Plus sensor, people only need two sensors a month, which ensures both a more convenient and more affordable experience.” 

Last November, Abbott secured the US FDA approval for its molecular human papillomavirus screening solution, an addition to the Alinity m diagnostic assay family.